956-30-9

Basic information

• Product Name: 2-AMINO-N-(2-CHLOROPYRIDIN-3-YL)BENZAMIDE
• Synonyms: 2-AMINO-N-(2-CHLOROPYRIDIN-3-YL)BENZAMIDE;o-amino-N-(2-chloro-3-pyridyl)benzamide;2-Amino-N-(2-chloro-3-pyridyl)benzamide;N-(2-Chloro-3-pyridyl)-2-aminobenzamide;2-azanyl-N-(2-chloropyridin-3-yl)benzamide
• CAS NO: 956-30-9
• Molecular Formula: C₁₂H₁₀ClN₃O
• Molecular Weight: 247.68
• EINECS: 213-478-2
• Product Categories: pharmacetical
• Mol File: 956-30-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 354.9°Cat760mmHg
• Flash Point: 168.4°C
• Appearance: /
• Density: 1.409g/cm³
• Vapor Pressure: 3.25E-05mmHg at 25°C
• Refractive Index: 1.701
• CAS DataBase Reference: 2-AMINO-N-(2-CHLOROPYRIDIN-3-YL)BENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-N-(2-CHLOROPYRIDIN-3-YL)BENZAMIDE(956-30-9)
• EPA Substance Registry System: 2-AMINO-N-(2-CHLOROPYRIDIN-3-YL)BENZAMIDE(956-30-9)

Safety Data

• Hazardous Substances Data: 956-30-9(Hazardous Substances Data)

Usage

General Description

2-AMINO-N-(2-CHLOROPYRIDIN-3-YL)BENZAMIDE is a chemical compound with the molecular formula C13H10ClN3O. It is a benzamide derivative with an amino group and a chloropyridin group attached to the benzene ring. 2-AMINO-N-(2-CHLOROPYRIDIN-3-YL)BENZAMIDE is often used in pharmaceutical research and drug development due to its potential biological activities. It is commonly used as a building block in the synthesis of various pharmaceutical compounds and has been studied for its potential as an anti-cancer and anti-inflammatory agent. Additionally, it is used as a reagent in chemical reactions and synthesis processes.

InChI:InChI=1/C12H10ClN3O/c13-11-10(6-3-7-15-11)16-12(17)8-4-1-2-5-9(8)14/h1-7H,14H2,(H,16,17)

Upstream product

• 610-14-0 2-nitrobenzyl chloride 
• 552-16-9 ortho-nitrobenzoic acid 
• 1028-86-0 N-(2-chloro-pyridin-3-yl)-2-nitro-benzamide 
• 84446-21-9 3-(2'-chlorobenzoyl)amino-2-chloropyridine 

Downstream Products

• 88369-52-2 3-(2'-acetylaminobenzoyl)amino-2-chloropyridine 
• 885-70-1 5H-benzo[e]pyrido[3,2-b][1,4]diazepin-6(11H)-one 
• 88369-59-9 6-amino-11H-pyrido<2,1-b>quinazolin-11-one 
• 142670-87-9 N-benzyl-N-(2-chloro-3-pyridinyl)amine 
• 509953-51-9 2-chloro-N-(4-methylphenyl)pyridin-3-ylamine 
• 509953-53-1 2-chloro-N-(4-methoxyphenyl)pyridin-3-ylamine 
• 793675-14-6 N-(2-chloro-3-pyridinyl)-N-phenylamine 
• 830324-73-7 3-(2-chloro-pyridin-3-yl)-4-oxo-3,4-dihydro-quinazoline-2-carboxylic acid phenylamide 
• 830324-76-0 N-benzyl-3-(2-chloro-3-pyridyl)-3,4-dihydro-4-oxo-2-quinazolinecarboxamide 
• 830324-69-1 3,4-dihydro-4-oxo-3-(2-chloro-3-pyridyl)-2-quinazolinecarbothioic acid S-p-tolyl ester 
• 830324-74-8 3-(2-chloro-pyridin-3-yl)-4-oxo-3,4-dihydro-quinazoline-2-carboxylic acid (4-methoxy-phenyl)-amide 
• 830324-77-1 3-(2-chloro-pyridin-3-yl)-4-oxo-3,4-dihydro-quinazoline-2-carboxylic acid phenethyl-amide 
• 830324-75-9 3-(2-chloro-pyridin-3-yl)-4-oxo-3,4-dihydro-quinazoline-2-carboxylic acid (4-trifluoromethyl-phenyl)-amide 
• 830324-70-4 3-(2-chloro-pyridin-3-yl)-4-oxo-3,4-dihydro-quinazoline-2-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide 

Relevant articles and documents

AZABICYCLO AND DIAZEPINE DERIVATIVES FOR TREATING OCULAR DISORDERS

The present invention provides in one aspect azabicycio and diazepine derivatives useful as modulators of muscarinic receptors. In another aspect, the present invention provides pharmaceutical compositions for treating ocular diseases, the compositions comprising at least one muscarinic receptor modulator. Formulae (I) & (II):

MUSCARINIC ANTAGONISTS WITH PARP AND SIR MODULATING ACTIVITY AS CYTOPROTECTIVE AGENTS

The present invention relates to generally to the cytoprotective activity of mixed muscarinic inhibition/PARP modulation and in particular to the use of dual inhibitors of M1 muscarinic receptor and poly(ADP-ribose) polymerase (PARP) as neuroprotective medicaments, particularly as medicaments for the prevention and/or treatment of neurological diseases. Particularly preferred compounds are condensed diazepinones, e.g. condensed benzodiazepinones such as pirenzepine or compounds which are metabolized to condensed benzodiazepinones such as olanzapine.

New pyridobenzodiazepine derivatives as potential antipsychotics: Synthesis and neurochemical study

The discovery of a new, safe, atypical antipsychotic remains an important challenge. To achieve this goal, a series of N-methylpiperazinopyrido[2,3- b][1,4]- and -[1,5]- and -pyrido[4,3-b][1,4]- and -[1,5]-benzodiazepines were synthesized. The dopaminergic (D1, D2), serotonergic (5-HT2), and cholinergic (M) affinities, frequently remarked in the action mechanisms of antipsychotic drugs, were determined using their respective in vitro receptor binding assays. All affinities were reduced for each compound. Optimal substituents were found to be in the 2- or 8-position for the retention of affinities, while substitution at the 5-position by acyl or alkyl groups dramatically diminished binding affinities. Pyridobenzodiazepine derivatives, such as clozapine, were found to be inactive or only weakly effective against apomorphine-mediated stereotypes in rats. In an original and complex behavioral model developed in dogs and successfully used to differentiate distinct classes of psychotropic drugs and to discriminate between typical and atypical neuroleptic drugs, 8-chloro-6-(4-methyl-1-piperazinyl)-11H- pyrido[2,3-b][1,4]benzodiazepine (9), 8-methyl-6-(4-methyl-1-piperazinyl)- 11H-pyrido[2,3-b][1,4]benzodiazepine (12), and 5-(4-methyl-1-piperazinyl)- 11H-pyrido[2,3-b][1,5]benzodiazepine (16) showed most of the behavioral characteristics previously described for neuroleptics. Their neurochemical profiles, particularly their 5-HT2/D2 pK(i) ratios, were compatible with an atypical antipsychotic effect. These compounds were selected for further investigation. The proposed modulations could lead to new possibilities for the pharmacochemistry of diarylazepines.